Protamine Zinc Insulin Veterinary Grade API

Protamine Zinc Insulin Veterinary Grade API is supplied as a sterile white to off-white crystalline suspension or lyophilised intermediate. Product designations PZI-VG-40 and PZI-VG-100 denote the nominal insulin activity after reconstitution: 40 IU/mL and 100 IU/mL, respectively. The material is released against potency, protamine-to-insulin molar ratio, zinc-to-insulin molar ratio, pH, particle size distribution after resuspension, bacterial endotoxin, sterility, and subvisible particulate matter. It is intended for processing into injectable suspensions and, with appropriate stabilisation and enteric protection, into solid dosage intermediates such as tablets, capsules, powders, granules, and premixes for veterinary use. The API is not interchangeable with regular insulin, NPH, or lente products without a revised bioequivalence assessment.

PZI-VG-100 is filled into Type I borosilicate glass vials of 10 mL nominal fill. The closure is a chlorobutyl rubber stopper with an aluminium flip-off seal. Unopened vials are stored at 2–8°C protected from light. In-use vials may be held at controlled room temperature for up to 28 days, but repeated temperature cycling above 25°C increases free insulin in the supernatant and alters the depot profile. Before dose withdrawal, the vial is resuspended by gentle inversion 10–20 times. Vigorous shaking introduces air and shears the crystalline particles; this can narrow the particle size distribution and produce faster dissolution after injection.

What distinguishes protamine zinc insulin from isophane and lente insulin in veterinary compounding?

Protamine zinc insulin contains an excess of protamine sulfate and zinc chloride relative to neutral protamine Hagedorn isophane. This excess stabilises a slowly dissociating crystal lattice with reduced dissolution rate in subcutaneous tissue. In NPH, insulin and protamine are combined at an isophane ratio, yielding intermediate-acting particles; in PZI, the higher zinc content prolongs dissociation and delays release. Lente and ultralente preparations lack protamine and rely on zinc-acetate crystallinity, producing a different dissolution profile and particle morphology. Regular soluble insulin remains in solution and has an immediate time-action profile. The consequence is that PZI has a slower onset and a longer duration than NPH or lente in veterinary patients, but the profile shifts with particle size distribution, crystal form, injection site vascularity, and species-specific subcutaneous pH and temperature.

Because the unit activity is standardised by biological assay, a unit of PZI is not clinically interchangeable with a unit of NPH or lente without re-titration. Published veterinary pharmacokinetic data in diabetic cats document duration of action of 12–24 h after subcutaneous injection; however, the data are product-specific and should not be extrapolated to compounded formulations without validation by a qualified assay.

Release specifications and depot-forming variables

The release specification for PZI-VG-100 sterile suspension requires resuspendability without irreversible agglomeration after storage at 2–8°C. The pH window is 7.0–7.4; outside this range, the crystalline fraction may dissolve or amorphous precipitate forms, shifting dissolution rate. Zinc and protamine ratios are monitored by inductively coupled plasma optical emission spectrometry and high-performance liquid chromatography, respectively. Batch-to-batch variation in particle size is controlled by laser diffraction: D50 is typically held between 8 µm and 25 µm after standardised resuspension in the finished suspension. Smaller D50 values increase surface area and shorten the profile; larger D50 values reduce injectability through 29-gauge needles. These parameters are critical because the depot effect is a function of crystal dissolution kinetics, not only insulin potency.

For lyophilised PZI, residual moisture is held at or below 3.0% w/w; higher moisture reduces storage stability. The powder is hygroscopic and is packaged under dry nitrogen. Supernatant insulin after 24 h of undisturbed settling is controlled below 2.0 IU/mL in the finished sterile suspension because elevated free insulin indicates premature crystal dissociation. The crystalline fraction is characterised by optical microscopy and laser diffraction at batch release; crystal habit should be predominantly rod-shaped. Equiaxed or fragmented particles are recorded as observation and may require additional resuspension studies if present above the acceptance threshold stated in the certificate of analysis.

In a 316L stainless steel jacketed vessel, sterile-filtered insulin solution is cooled to 2–4°C before the addition of sterile protamine sulfate and zinc chloride solutions. Crystal growth is conducted under low-shear impeller agitation at 30–60 rpm. Increasing agitation above 500 rpm during crystallisation increases fines and narrows the crystal size distribution but can generate amorphous fragments that dissolve too rapidly after injection. The final suspension is passed through a 150 µm screen to remove agglomerates, then filled aseptically in an ISO 5 environment. Terminal moist heat sterilisation is not used because insulin denatures above 55°C; all components are sterile-filtered or dry-heat sterilised before crystallisation. Sterile filtration of the finished suspension is not possible because the crystalline particles exceed 0.22 µm membrane pores. Filler and stopper preparation comply with ISO 14644 and EU GMP Annex 1 for aseptic processing. During scale-up from pilot to production, batch-to-batch variance is observed mainly in crystal aspect ratio and D50. Deviations in zinc addition of ±5% from the registered ratio can shift the dissolution time-action curve; therefore, the zinc stock solution is standardised by complexometric titration before use.

A clear injectable solution can be produced from the API only by dissociating the zinc-protamine complex under acidic conditions. This yields a regular insulin-like immediate-acting profile and is not the standard PZI presentation. Such processing is not recommended unless the formulation is re-established as a separate solution product and the protamine and zinc counterions are removed or neutralised in a controlled manner. The standard injectable presentation remains a suspension; it must not be injected intravenously.

Assessing the analytical release and degradation profile of PZI-VG-100

Potency is determined by high-performance liquid chromatography using a reversed-phase C18 column and gradient elution with phosphate buffer and acetonitrile; the method is system suitability tested per USP 121. The assay must resolve insulin from desamido insulin and other related peptides. Size-exclusion HPLC monitors high-molecular-weight proteins and aggregates; the acceptance limit for high-molecular-weight species is product-specific but typically below 1.0% of total peak area. Deamido insulin is controlled as an impurity; the compendial monograph sets its limit below 3.0–4.0% for many insulin products, but the exact PZI limit is stated in the certificate of analysis. Peptide mapping after digestion with endoproteinase Glu-C confirms the primary structure, and mass spectrometry is used for identification. Dissolution testing of the final suspension is performed in a pH 7.4 phosphate-buffered saline medium at 37°C using a USP 711 apparatus 2 paddle at 50 rpm. The time to release 50% insulin is monitored as an in vitro indicator of depot duration; a shorter T50 indicates faster dissolution and potential loss of long-acting character.

Stability storage conditions follow ICH Q1A(R2) for refrigerated products: 5°C ± 3°C long-term, 25°C ± 2°C/60% RH ± 5% RH accelerated. Release and shelf-life acceptance criteria are product-specific and stated in the stability protocol. At 1–5°C, the sterile suspension retains potency within the specified range for the assigned shelf-life; stressed exposure to 40°C for 7 days reduces potency in representative samples because insulin deamidation and aggregation accelerate above refrigerated conditions. Published data for this specific accelerated configuration is limited; therefore, product-specific degradation rates are established from the manufacturer’s stability batches rather than from general protein literature.

When the API is dry-milled for tablet, capsule, granule and premix intermediates

Dry processing of protamine zinc insulin is constrained by moisture, temperature, and mechanical energy. Lyophilised PZI is milled under nitrogen with residual moisture below 3.0% w/w; milling above 40°C or at high relative humidity causes denaturation and loss of potency. Dry granulation by roller compaction is preferred over wet granulation because water exposure dissolves the zinc-protamine complex and promotes amorphous aggregation. If wet granulation is unavoidable, non-aqueous solvents such as anhydrous ethanol or isopropanol may be used, but the granulation endpoint must be validated by recovery of insulin potency above 90.0% label claim. Tablets and capsules containing PZI require an enteric coating. Gastric pepsin degrades insulin rapidly at pH 1.5–2.5; uncoated oral products exhibit negligible systemic absorption. Methacrylic acid–ethyl acrylate copolymer enteric coatings are commonly used, but dissolution at pH 5.5–6.5 must be confirmed for the target species intestinal environment. Premix and powder intermediates are dispersible in feed carriers such as lactose monohydrate and microcrystalline cellulose, but this does not confer oral bioavailability unless the final dosage form includes an absorption-enhancing system.

Published data for oral administration of intact protamine zinc insulin in dogs and cats is limited, and the oral route is not a standard approach. Compounded tablet and capsule preparations are therefore considered non-systemic unless bioavailability is demonstrated by a validated ELISA or HPLC-MS method. In solid dosage processing, the dry blend must be protected from atmospheric moisture; environmental relative humidity above 60% requires preconditioning of excipients and processing under dry nitrogen. Lubrication with magnesium stearate is limited to 0.5–1.0% w/w because extended mixing can shear the insulin particles and expose hydrophobic surfaces, reducing dissolution. Disintegration testing per USP 2040 is performed in simulated gastric fluid and simulated intestinal fluid to confirm enteric coat integrity. For granules and premixes, content uniformity is assessed by sampling at 10–15 points across the blender; acceptance is 90.0–110.0% label claim with relative standard deviation below 5.0%. These operations are common to low-dose protein APIs and require separate equipment or validated cleaning procedures compliant with 21 CFR 211 for veterinary drug products where applicable.

Cross-contamination control follows 21 CFR 211.67. Swab sampling after cleaning uses a limit of not more than 10 ppm in the next product unless a health-based limit is established. Dedicated equipment is preferred for veterinary insulin products; if shared, cleaning validation must include HPLC and ELISA to detect residual insulin and protamine in rinse water and surface swabs. These controls are necessary because protamine zinc insulin is active at microgram-level doses and residual crystalline material can produce measurable hypoglycaemic response if transferred to a subsequent batch.